Immunitybio Inc (IBRX)

Dec 05, 2025

ImmunityBio, Inc. (IBRX): A Bull Case Theory - Finviz

Dec 05, 2025

Dec 05, 2025

ImmunityBio, Inc. (IBRX): A bull case theory - MSN

Dec 05, 2025

Dec 05, 2025

Can ImmunityBio Stock Hold Up When Markets Turn? - Trefis

Dec 05, 2025

Dec 05, 2025

Is ImmunityBio Inc. stock a smart buy before Fed meeting2025 Price Targets & Safe Entry Zone Tips - Newser

Dec 05, 2025

Dec 05, 2025

Will ImmunityBio Inc. (26CA) stock benefit from mergersJuly 2025 Price Swings & Breakout Confirmation Alerts - Newser

Dec 05, 2025

Dec 04, 2025

How ImmunityBio Inc. (26CA) stock responds to bond marketJuly 2025 Drop Watch & Intraday High Probability Alerts - Newser

Dec 04, 2025

Dec 04, 2025

Piper Sandler Remains a Buy on ImmunityBio (IBRX) - The Globe and Mail

Dec 04, 2025

Dec 04, 2025

ImmunityBio Earnings Notes - Trefis

Dec 04, 2025

Dec 04, 2025

Is ImmunityBio Inc. (26CA) stock undervalued at current priceWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser

Dec 04, 2025

Dec 03, 2025

ImmunityBio (NASDAQ:IBRX) Trading Down 5.4%Should You Sell? - MarketBeat

Dec 03, 2025

Dec 03, 2025

Lawmakers Invited to FDA Meeting for Soon-Shiong’s Drug - Bloomberg.com

Dec 03, 2025

Dec 03, 2025

ImmunityBio (IBRX) Slashes 9% on Lack of Leads - Finviz

Dec 03, 2025

Dec 03, 2025

Lawmakers Invited to FDA Meeting for Patrick Soon-Shiong’s Drug - Bloomberg.com

Dec 03, 2025

Dec 03, 2025

A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs (NASDAQ:IBRX) - Seeking Alpha

Dec 03, 2025

Dec 03, 2025

Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? - MSN

Dec 03, 2025

Dec 03, 2025

ImmunityBio (IBRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 03, 2025

Dec 02, 2025

ImmunityBio (NASDAQ:IBRX) Sees Large Volume IncreaseStill a Buy? - MarketBeat

Dec 02, 2025

Dec 02, 2025

ImmunityBio Stock Rises Despite Financial Challenges - timothysykes.com

Dec 02, 2025

Dec 02, 2025

Can ImmunityBio Inc. (26CA) stock sustain free cash flowRisk Management & Reliable Volume Spike Trade Alerts - Newser

Dec 02, 2025

Dec 02, 2025

Geode Capital Management LLC Acquires 1,487,849 Shares of ImmunityBio, Inc. $IBRX - MarketBeat

Dec 02, 2025

Dec 01, 2025

Assessing ImmunityBio After Recent Cancer Immunotherapy Headlines and Ongoing Stock Volatility - Yahoo Finance

Dec 01, 2025

Dec 01, 2025

A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally - Yahoo Finance

Dec 01, 2025

Dec 01, 2025

ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences - Insider Monkey

Dec 01, 2025

Nov 30, 2025

ImmunityBio Skyrockets on Positive Trial Results and Sales Growth - StocksToTrade

Nov 30, 2025

Nov 30, 2025

ImmunityBio Boosts Outlook with Strong Revenue Growth and Clinical Advances - timothysykes.com

Nov 30, 2025

Nov 30, 2025

ImmunityBio’s Immunotherapy Focus Boosts Market Expectations - StocksToTrade

Nov 30, 2025

Nov 30, 2025

ImmunityBio Gains Momentum with Strong ANKTIVA Sales and Clinical Advances - timothysykes.com

Nov 30, 2025

Nov 30, 2025

10 Stocks Racking Up Big Gains - Insider Monkey

Nov 30, 2025

Nov 29, 2025

ImmunityBio Stock Boosted by Rising Demand for ANKTIVA and Positive Clinical Trials - StocksToTrade

Nov 29, 2025

Nov 29, 2025

ImmunityBio’s Strong Market Position Boosted by Recent Innovations - timothysykes.com

Nov 29, 2025

Nov 29, 2025

HEIGHTS CAPITAL MANAGEMENT, INC's ImmunityBio Inc(IBRX) Holding History - GuruFocus

Nov 29, 2025

Nov 29, 2025

ImmunityBio’s Clinical Advances and Sales Boost Highlight Market Optimism - StocksToTrade

Nov 29, 2025

Nov 29, 2025

ImmunityBio Stock (IBRX) Opinions on Q3 Revenue Growth - Quiver Quantitative

Nov 29, 2025

Nov 29, 2025

ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's Why - MarketBeat

Nov 29, 2025

Nov 29, 2025

Some Confidence Is Lacking In ImmunityBio, Inc.'s (NASDAQ:IBRX) P/S - 富途牛牛

Nov 29, 2025

Nov 29, 2025

ImmunityBio’s Strategic Developments and Financial Growth Fuel Optimism - timothysykes.com

Nov 29, 2025

Nov 29, 2025

ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning? - ts2.tech

Nov 29, 2025

Nov 28, 2025

Why ImmunityBio (IBRX) Is Up 13.5% After Strong Q3 Anktiva Revenue Surge Announced at Jefferies London - simplywall.st

Nov 28, 2025

Nov 28, 2025

ImmunityBio Stock Surges Amid Growing Demand and Clinical Success - StocksToTrade

Nov 28, 2025

Nov 28, 2025

ImmunityBio’s Remarkable Growth: Unpacking the Surge - StocksToTrade

Nov 28, 2025

Nov 28, 2025

ImmunityBio Explores Innovations in Cancer Treatment - timothysykes.com

Nov 28, 2025

Nov 28, 2025

ImmunityBio (IBRX) Stock Forecast and Price Target 2025 - MarketBeat

Nov 28, 2025

Nov 27, 2025

ImmunityBio (IBRX): Evaluating Valuation After Q3 Revenue Growth and Operational Improvements - simplywall.st

Nov 27, 2025

Nov 27, 2025

A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know - AOL.com

Nov 27, 2025

Nov 26, 2025

What to know about Anktiva, the cancer drug that doesn’t use chemotherapy - NewsNation

Nov 26, 2025

Nov 26, 2025

How does nonchemotherapy cancer treatment Anktiva work? - NewsNation

Nov 26, 2025